Board Member
TerrAscend Corp. (TSNDF)Board Member
Heron Therapeutics, Inc. (HRTX)Equibles does not estimate personal net worth.
Get an email with a short summary when TerrAscend Corp. publishes a filing, an earnings call transcript or a press release.
Get TSNDF alertsCraig Collard is recorded as Board Member at TerrAscend Corp. (TSNDF), Board Member at Heron Therapeutics, Inc. (HRTX) since January 1, 2023 and CEO at Heron Therapeutics, Inc. (HRTX). The newest filing on record that lists Craig Collard as Board Member at TerrAscend Corp. (TSNDF) is dated April 16, 2026. The newest filing on record that lists Craig Collard as CEO and Board Member at Heron Therapeutics, Inc. (HRTX) is dated April 30, 2026. TerrAscend Corp. reported in an 8-K filed June 15, 2026 that Craig Collard was appointed Director, effective June 9, 2026. TerrAscend Corp. reported in an 8-K filed June 24, 2025 that Craig Collard was appointed Director, effective June 24, 2025. Heron Therapeutics, Inc. reported in an 8-K filed June 18, 2024 that Craig Collard was appointed Director, effective June 13, 2024. Equibles holds 5 filed executive changes naming Craig Collard; each is listed under recent activity with its source filing. The proxy statement of Heron Therapeutics, Inc. reports total compensation of $3,516,291 for Craig Collard in fiscal 2025, including a base salary of $689,431. Disclosed compensation is on record for 4 fiscal years. Craig Collard has spoken on 13 earnings calls across 1 company, most recently for Heron Therapeutics, Inc. on August 10, 2026. Heron Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. TerrAscend Corp. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Heron Therapeutics, Inc. includes Adam Morgan (Chairman and Board Member), Ira Duarte (CFO and Chief Accounting Officer), Mark Hensley (COO) and 7 others.
“Each of the five individuals listed below was elected at the Annual Meeting to serve on the Company’s Board of Directors (the "Board") until the close of the next annual meeting of shareholders of the Company following his or her election, or any postponement(s) or adjournment(s) thereof, unless his or her office is vacated earlier or until his or her successor is elected or appointed.”
“Each of the five individuals listed below was elected at the Annual Meeting to serve on the Company's Board of Directors (the "Board") until the close of the next annual meeting of shareholders of the Company following his or her election, or any postponement(s) or adjournment(s) thereof, unless his or her office is vacated earlier or until his or her successor is elected or appointed.”
“Net revenue for the quarter was $37.7 million. That is growth from the first quarter, but it is below what we expected of ourselves. Sinvati sales were up compared to Q1 in a highly competitive market, and Zendralev grew 35% year-over-year, but both were slower than we anticipated.”
“Today, we're thrilled to share our financial results and provide commercial updates on our business. I'd like to begin by highlighting several key accomplishments.”
“Hello, everyone, and welcome to the Heron Therapeutics fourth quarter and full year 2025 earnings call. Today, we're thrilled to share our financial results and provide commercial updates on our business.”
“Today, we're thrilled to share our third quarter results and provide insight into how product sales are trending. I'd like to begin by highlighting several key accomplishments from the quarter.”
“Good morning, everyone, and welcome to Heron Therapeutics First Quarter 2025 Earnings Call. Today, we are extremely excited to share our results for the first quarter of 2025.”
2023-01-01–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 16, 2026
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CEO, Board Member
2023-01-01–present
TSNDF
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Heron Therapeutics, Inc. (HRTX) | Chief Executive Officer | $689,431 | $3,516,291 |
| 2024 | Heron Therapeutics, Inc. (HRTX) | Chief Executive Officer | $515,000 | $1,424,811 |
| 2023 | Heron Therapeutics, Inc. (HRTX) | Chief Executive Officer | $492,986 | $10,775,818 |
| 2022 | Heron Therapeutics, Inc. (HRTX) | Chief Executive Officer | — | — |
